
    
      To determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose
      (RP2D) of single agent ISB 1302 in subjects with HER2-positive metastatic breast cancer who
      have been treated with all known therapies known to confer clinical benefit.
    
  